Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Name:
Wolleschak et al_final.pdf
Size:
2.276Mb
Format:
PDF
Description:
Open Access Publication
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Wolleschak, DeniseMack, Thomas S
Perner, Florian
Frey, Stephanie
Schnöder, Tina M
Wagner, Marie-Christine
Höding, Christine
Pils, Marina C
Parkner, Andreas
Kliche, Stefanie
Schraven, Burkhart
Hebel, Katrin
Brunner-Weinzierl, Monika
Ranjan, Satish
Isermann, Berend
Lipka, Daniel B
Fischer, Thomas
Heidel, Florian H
Issue Date
2014-06
Metadata
Show full item recordCitation
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. 2014, 99 (6):e90-3 HaematologicaJournal
HaematologicaPubMed ID
24633870Type
articleLanguage
enISSN
1592-8721ae974a485f413a2113503eed53cd6c53
10.3324/haematol.2014.104331
Scopus Count
The following license files are associated with this item:
Related articles
- Availability of FLT3 inhibitors: how do we use them?
- Authors: Perl AE
- Issue date: 2019 Aug 29
- Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
- Authors: Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, Bug G, Heinzel T, Böhmer FD, Krämer OH
- Issue date: 2012 Nov
- Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
- Authors: Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, Adamia S, Sattler M, Stone R, Griffin JD
- Issue date: 2020 Mar
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
- Authors: Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP
- Issue date: 2013 Apr 18
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
- Authors: Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM
- Issue date: 2013 Mar 7